Arrowhead Pharmaceuticals (ARWR) Change in Acquisitions & Divestments (2011 - 2026)

Arrowhead Pharmaceuticals' Change in Acquisitions & Divestments history runs 15 years deep, the most recent figure standing at $9.2 million for Q1 2026.

• Quarterly Change in Acquisitions & Divestments fell 96.0% year-over-year to $9.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $466.7 million (down 19.68% YoY) and the FY2025 annual result came in at $689.6 million, up 55.9% from the prior year.
• Change in Acquisitions & Divestments was $9.2 million for Q1 2026 at Arrowhead Pharmaceuticals, down from $115.3 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $240.5 million in Q2 2025 and bottomed at $9.2 million in Q1 2026.
• A 5-year average of $106.8 million and a median of $101.8 million in 2025 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2023 — Change in Acquisitions & Divestments jumped 314.42% — and 2026, when it tumbled 96.0%.
• Arrowhead Pharmaceuticals' Change in Acquisitions & Divestments stood at $69.4 million in 2022, then soared by 92.31% to $133.5 million in 2023, then declined by 11.48% to $118.2 million in 2024, then slipped by 2.4% to $115.3 million in 2025, then tumbled by 92.04% to $9.2 million in 2026.
• Business Quant data shows ARWR's Change in Acquisitions & Divestments at $9.2 million in Q1 2026, $115.3 million in Q4 2025, and $101.8 million in Q3 2025.